Opsens

Haemonetics (NYSE: HAE) + announced today that it completed its previously announced acquisition of cardiology-focused medical device company OpSens.

Boston-based Haemonetics first announced plans to buy OpSens for more than $250 million in October. Upon completion of the deal, the company acquired all outstanding shares at a fully diluted equity value of about $255 million. As a result, OpSens common shares ceased trading in the public market and will be delisted from the Toronto Stock Exchange.

OpSens offers optical technology for use in interventional cardiology. Core products include the SavvyWire, a sensor-guided, 3-in-1 guidewire for transcatheter aortic valve replacement (TAVR) procedures. SavvyWire acts as a pacing and pressure monitoring wire, advancing procedure workflow and enabling shorter hospital stays.

The company’s OptoWire pressure guidewire aims to improve clinical outcomes by measuring F…

Haemonetics (NYSE: HAE) + today announced a definitive agreement to acquire cardiology-focused technology developer OpSens.

Boston-based Haemonetics will acquire all outstanding shares of Opsens for CAD $2.90 in an all-cash transaction that will have a fully diluted equity value of approximately $253 million USD. The transaction is expected to close by the end of January 2024.

Opsens develops optical technology for use in interventional cardiology. Its products include the SavvyWire and OptoWire.

SavvyWire is a sensor-guided 3-in-1 guide wire for TAVR procedures that acts as a pacing and pressure monitoring wire that advances the workflow of the procedure for shorter hospital stays. OptoWire is a pressure guide wire that aims to improve clinical outcomes by accurately and consistently measuring fractional flow reserve (FFR) and diastolic pressure ratio to help clinicians in the diagnosis and treatment of coronary …